TG
KIN

TCW Group’s Kindred Biosciences, Inc. KIN Stock Holding History

TCW Group’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-98,363
Closed -$1.82M – 768
2014
Q1 		$1.82M Sell
98,363
-46,336
-32% -$883K 0.01% 676
2013
Q4 		$1.61M Buy
+144,699
New +$1.72M 0.01% 692

Other funds holding KIN

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCW Group's KIN Position: Q2 2014 in Review

TCW Group sold out of Kindred Biosciences, Inc. (KIN) in Q2 2014, closing a stake of 98,363 shares — an estimated $1.82M sold.

TCW Group first reported a position in KIN in Q4 2013 and held it in 2 quarters. The position peaked at $1.82M in Q1 2014. 56 funds tracked by Wall St. Rank hold KIN as of Q2 2014.

  • TCW Group reported no remaining Kindred Biosciences, Inc. position as of Q2 2014 after selling out during the quarter.
  • TCW Group sold 98,363 Kindred Biosciences, Inc. shares in Q2 2014, an estimated $1.82M.
  • TCW Group first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 2 quarters.
  • TCW Group's Kindred Biosciences, Inc. position peaked at $1.82M in Q1 2014.
  • 56 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2014.

Based on TCW Group's 13F filing for Q2 2014, filed 14 Aug 2014.